Skip to main content

Advertisement

Table 6 Statistical analysis of the difference between proportions of NVP-related adverse reactions of skin and liver

From: Assessment of the nevirapine safety signal using data from the national antiretroviral dispensing database: a retrospective study

    % (95 % CI)  
Adverse reaction type 2011 Previous years P-value
ARV Related reactions (all) 80.9 % (77.4 %–84.4 %) 81.3 % (78.1 %–84.5 %) 0.87
NVP-related Skin and liver 43.2 % (38.7 %–47.7 %) 16.7 % (13.7 %–19.7 %) <0.0001
Skin (all) 31.2 % (27.0 %–35.5 %) 11.8 % (9.2 %–14.4 %) <0.0001
Skin: severe 22.7 % (18.9 %–26.5 %) 5.6 % (3.7 %%–7.5 %) <0.0001
Skin: mild/moderate 8.5 % (6.0 %–11.0 %) 6.2 % (4.2 %–8.2 %) 0.16
Liver (all) 12.1 % (9.2 %–15.0 %) 4.9 % (3.1 %–6.7 %) <0.0001
Liver: severe 8.5 % (6.0 %–11.0 %) 2.2 % (1.0 %–3.4 %) <0.0001
Liver: mild/moderate 2.7 % (1.0 %–4.4 %) 2.4 % (1.2 %–3.6 %) 0.73
Other medicines Skin and liver 5.0 % (3.0 %–7.0 %) 9.9 % (7.5 %–12.3 %) 0.002
NVP-related reactions for Females 29.5 % (25.4 %–33.6 %) 12.5 % (9.8 %–15.2 %) <0.0001
Females: severe 21.6 % (17.9 %–25.3 %) 5.6 % (3.7 %–7.5 %) <0.0001
Females: skin-severe 17.3 % (13.9 %–20.7 %) 4.0 % (2.4 %–5.6 %) <0.0001
Females: liver-severe 4.3 % (2.5 %–6.1 %) 1.5 % (0.5 %–2.5 %) 0.0072
Males 13.7 % (10.6 %–16.8 %) 3.9 % (2.3 %–5.5 %) <0.0001
Males: severe 9.6 % (6.9 %–12.3 %) 2.2 % (1.0 %–3.4 %) <0.0001
Males: skin-severe 5.4 % (3.4 %–7.4 %) 1.5 % (0.5 %–2.5 %) 0.0007
Males: liver-severe 4.2 % (2.4 %–6.0 %) 0.7 % (0.0 %–1.4 %) 0.0003
  1. The results in the above table show that there was an increase in proportion of reports of severe reactions to NVP, on the skin and liver. The results also show that there was no increase in the mild and moderate reactions